Literature DB >> 3338076

In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo.

S P Robinson1, R Koch, V C Jordan.   

Abstract

A series of 2-phenyl-1-ethyl-3-methylindoles with or without a hydroxyl group in the para position of the phenyl ring and the 5 or 6 position of the indole nucleus were compared with 17 beta-estradiol in the stimulation of (a) prolactin production in rat pituitary cells in primary culture, (b) progesterone receptor synthesis in MCF-7 cells, and (c) proliferation of MCF-7 cells. All compounds were less active than estradiol but all derivatives including D15414, the hydroxylated metabolite of D16726 (zindoxifene, a known antitumor agent against mammary cancer) were fully estrogenic. Hydroxyl groups at the para position of the phenyl ring and 6 position of the indole nucleus conferred the highest estrogen potency [ED50 (drug concentration producing 50% of maximum activity) in all assays around 10(-10) M]. Moving or eliminating the hydroxyl on the indole ring markedly reduced the estrogen potency; however, an even more dramatic reduction in estrogenic activity was produced by removing the hydroxyl of the phenyl ring.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3338076

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis?

Authors:  V Craig Jordan
Journal:  Menopause       Date:  2014-10       Impact factor: 2.953

Review 2.  The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.

Authors:  Ping Fan; Philipp Y Maximov; Ramona F Curpan; Balkees Abderrahman; V Craig Jordan
Journal:  Mol Cell Endocrinol       Date:  2015-06-05       Impact factor: 4.102

3.  The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture.

Authors:  V Craig Jordan
Journal:  Ann Surg Oncol       Date:  2019-03-25       Impact factor: 5.344

4.  The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators.

Authors:  V Craig Jordan; Russell McDaniel; Fadeke Agboke; Philipp Y Maximov
Journal:  Steroids       Date:  2014-06-17       Impact factor: 2.668

Review 5.  Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women's Health.

Authors:  Balkees Abderrahman; V Craig Jordan
Journal:  Endocrinology       Date:  2018-08-01       Impact factor: 4.736

Review 6.  Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team.

Authors:  V Craig Jordan
Journal:  Breast Cancer Res Treat       Date:  2021-08-16       Impact factor: 4.872

Review 7.  50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?

Authors:  V Craig Jordan
Journal:  Endocr Relat Cancer       Date:  2021-01       Impact factor: 5.678

Review 8.  The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice.

Authors:  Philipp Y Maximov; Theresa M Lee; V Craig Jordan
Journal:  Curr Clin Pharmacol       Date:  2013-05

9.  Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study.

Authors:  R C Stein; M Dowsett; D C Cunningham; J Davenport; H T Ford; J C Gazet; E von Angerer; R C Coombes
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.